Siklos™ (hydroxyurea) – New orphan drug approval
January 2, 2018 – The FDA announced the approval Addmedica’s Siklos (hydroxyurea), to reduce the frequency of painful crises and to reduce the need for blood transfusions in pediatric patients, 2 years of age and older, with sickle cell anemia with recurrent moderate to severe painful crises.
Top